Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20).

Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20).

Item
http://www.wikidata.org/entity/Q42869459
Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attackPeroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attackClinically and pharmacologically relevant interactions of antidiabetic drugsEffects of PPARs agonists on cardiac metabolism in littermate and cardiomyocyte-specific PPAR-γ-knockout (CM-PGKO) mice.Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings.G Protein-coupled Receptor 40 (GPR40) and Peroxisome Proliferator-activated Receptor γ (PPARγ): AN INTEGRATED TWO-RECEPTOR SIGNALING PATHWAY.Can the electrophysiological action of rosiglitazone explain its cardiac side effects?Thiazolidinedione safety.Examining the safety of PPAR agonists - current trends and future prospects.Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review.Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future.Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit.Editorial: Closing sale of innovative treatment options for the treatment of diabetes and metabolic disorders?Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack.Peroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair.Sodium-glucose co-transporter 2 inhibitors and the potential for cardiovascular risk reduction in patients with type 2 diabetes mellitus.
P2860

Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20).

Item
http://www.wikidata.org/entity/Q42869459
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Pioglitazone and the risk of c ...... ROactive study (PROactive 20).
@en
Pioglitazone and the risk of c ...... ROactive study (PROactive 20).
@nl
type
label
Pioglitazone and the risk of c ...... ROactive study (PROactive 20).
@en
Pioglitazone and the risk of c ...... ROactive study (PROactive 20).
@nl
prefLabel
Pioglitazone and the risk of c ...... ROactive study (PROactive 20).
@en
Pioglitazone and the risk of c ...... ROactive study (PROactive 20).
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P921
P356
P1433
P1476
Pioglitazone and the risk of c ...... ROactive study (PROactive 20).
@en
P2093
P2860
P304
P31
P356
10.1111/J.1753-0407.2010.00082.X
P433
P478
P577
P5875
P698
P921